Lomustine and bevacizumab in progressive glioblastoma
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase in progression-free survival.
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 16, 2017
|
| In: |
The New England journal of medicine
Year: 2017, Jahrgang: 377, Heft: 20, Pages: 1954-1963 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1707358 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1707358 Verlag, Volltext: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707358 
|
| Verfasserangaben: | Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A. Brandes, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M. Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Andreas von Deimling, Vassilis Golfinopoulos, Jacoline C. Bromberg, Michael Platten, Martin Klein, Martin J. van den Bent |
| Zusammenfassung: | The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase in progression-free survival. |
|---|---|
| Beschreibung: | Gesehen am 04.12.2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1707358 |